The pan‐caspase inhibitor Emricasan (IDN‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitis

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|3|953-966

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.3, 2015-03, pp. : 953-966

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of serum toll‐like receptors 2 and 4 in non‐alcoholic steatohepatitis and liver fibrosis

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 7, 2015-07 ,pp. : 1190-1196

John Wiley & Sons Inc

Access to resources Recommend Favorite

Diagnosis of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: Why liver biopsy is essential

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 64-66

John Wiley & Sons Inc

Access to resources Recommend Favorite

Novel non‐alcoholic steatohepatitis model with histopathological and insulin‐resistant features

By  

PATHOLOGY INTERNATIONAL, Vol. 68, Iss. 1, 2018-01 ,pp. : 12-22

John Wiley & Sons Inc

Access to resources Recommend Favorite

Diagnosis of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: Non‐invasive tests are enough

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 67-70

John Wiley & Sons Inc

Access to resources Recommend Favorite

Global epidemiology of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: What we need in the future

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 47-51

John Wiley & Sons Inc

Access to resources Recommend Favorite